United Therapeutics Stock Forecast, Price & News

-1.25 (-0.70 %)
(As of 06/15/2021 02:45 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,176 shs
Average Volume369,087 shs
Market Capitalization$7.99 billion
P/E Ratio19.71
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive UTHR News and Ratings via Email

Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

United Therapeutics logo

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.10 out of 5 stars

Medical Sector

91st out of 2,100 stocks

Pharmaceutical Preparations Industry

38th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 3.1 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

United Therapeutics (NASDAQ:UTHR) Frequently Asked Questions

Is United Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" United Therapeutics stock.
View analyst ratings for United Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than United Therapeutics?

Wall Street analysts have given United Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but United Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is United Therapeutics' next earnings date?

United Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for United Therapeutics

How were United Therapeutics' earnings last quarter?

United Therapeutics Co. (NASDAQ:UTHR) issued its quarterly earnings data on Wednesday, May, 5th. The biotechnology company reported $0.61 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $2.60 by $1.99. The biotechnology company earned $379.10 million during the quarter, compared to analyst estimates of $368.31 million. United Therapeutics had a net margin of 26.92% and a trailing twelve-month return on equity of 12.27%. The firm's quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.61 EPS.
View United Therapeutics' earnings history

How has United Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

United Therapeutics' stock was trading at $93.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, UTHR shares have increased by 88.6% and is now trading at $177.24.
View which stocks have been most impacted by COVID-19

What price target have analysts set for UTHR?

7 Wall Street analysts have issued twelve-month target prices for United Therapeutics' shares. Their forecasts range from $196.00 to $275.00. On average, they anticipate United Therapeutics' stock price to reach $227.14 in the next twelve months. This suggests a possible upside of 28.2% from the stock's current price.
View analysts' price targets for United Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are United Therapeutics' key executives?

United Therapeutics' management team includes the following people:
  • Dr. Martine A. Rothblatt, Founder, Chairman & CEO (Age 66, Pay $3.24M)
  • Mr. Michael I. Benkowitz, Pres & COO (Age 49, Pay $1.96M)
  • Mr. James C. Edgemond, CFO & Treasurer (Age 53, Pay $1.42M)
  • Mr. Paul A. Mahon, Exec. VP, Gen. Counsel & Corp. Sec. (Age 57, Pay $1.67M)
  • Mr. Dewey Steadman C.F.A., CFA, Head of Investor Relations
  • Ms. Holly Hobson, Associate VP of HR
  • Kevin T. Gray, Sr. VP of Strategic Operations & Logistics
  • Mr. Patrick Poisson, Exec. VP of Technical Operations (Age 53)
  • Mr. Gil Golden, Sr. VP & Chief Medical Officer
  • Leigh Peterson, VP of Product Devel.

What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO?

64 employees have rated United Therapeutics CEO Martine A. Rothblatt on Martine A. Rothblatt has an approval rating of 88% among United Therapeutics' employees.

Who are some of United Therapeutics' key competitors?

What other stocks do shareholders of United Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), (CELG), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE).

What is United Therapeutics' stock symbol?

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

Who are United Therapeutics' major shareholders?

United Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.85%), Renaissance Technologies LLC (7.16%), Acadian Asset Management LLC (2.33%), Dimensional Fund Advisors LP (1.68%), Palo Alto Investors LP (1.53%) and Nuveen Asset Management LLC (1.52%). Company insiders that own United Therapeutics stock include Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson.
View institutional ownership trends for United Therapeutics

Which major investors are selling United Therapeutics stock?

UTHR stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Dimensional Fund Advisors LP, D. E. Shaw & Co. Inc., Palo Alto Investors LP, Acadian Asset Management LLC, Tamarack Advisers LP, Krensavage Asset Management LLC, and BNP Paribas Arbitrage SA. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Patusky, Judy D Olian, Martine A Rothblatt, and Raymond Dwek.
View insider buying and selling activity for United Therapeutics
or view top insider-selling stocks.

Which major investors are buying United Therapeutics stock?

UTHR stock was acquired by a variety of institutional investors in the last quarter, including Polaris Capital Management LLC, Perceptive Advisors LLC, Bank of New York Mellon Corp, Assenagon Asset Management S.A., BlackRock Inc., Price T Rowe Associates Inc. MD, Royce & Associates LP, and Parkman Healthcare Partners LLC.
View insider buying and selling activity for United Therapeutics
or or view top insider-buying stocks.

How do I buy shares of United Therapeutics?

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is United Therapeutics' stock price today?

One share of UTHR stock can currently be purchased for approximately $177.24.

How much money does United Therapeutics make?

United Therapeutics has a market capitalization of $7.94 billion and generates $1.48 billion in revenue each year. The biotechnology company earns $514.80 million in net income (profit) each year or $11.54 on an earnings per share basis.

How many employees does United Therapeutics have?

United Therapeutics employs 950 workers across the globe.

When was United Therapeutics founded?

United Therapeutics was founded in 1996.

What is United Therapeutics' official website?

The official website for United Therapeutics is

Where are United Therapeutics' headquarters?

United Therapeutics is headquartered at 1040 SPRING ST, SILVER SPRING MD, 20910.

How can I contact United Therapeutics?

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]

This page was last updated on 6/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.